Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing for Rekovelle® (follitropin delta); alongside its existing unique ...

Pierre-Yves Berclaz, Chief Science and Medical Officer at Ferring Pharmaceuticals, stated: "The ADAPT-1 trial results confirm the efficacy and safety of follitropin delta across the full range of ...

These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications. 1,2 ...

The human microbiome market is projected to grow at a CAGR of 31% over the forecast period. Major factors driving growth ...

The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 women aged 18-40 years undergoing IVF or ICSI. 3 The trial compared the efficacy and safety of follitropin delta ...

The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 women aged 18-40 years undergoing IVF or ICSI. 3 The trial compared the efficacy and safety of follitropin delta and ...

As Direct Meds continues its growth trajectory, the company remains committed to using AI to scale care delivery while preserving the personal, nurse-supported experience it’s known for.

Pharmalittle: We’re reading about the gray market for obesity meds, an RSV drug recommendation, and more CDC advisory panel, selected by RFK Jr., recommends thimerosal be dropped from flu vaccines ...

Major insurance changes are coming to GLP-1 drugs for weight loss. Here’s what to know ...

ImmunityBio’s ANKTIVA shows promise, but modest growth, high cash burn, and rising competition raise red flags. Read why IBRX stock is a sell.